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ABSTRACT 
Ever since Paul Ehrlich, Nobel Prize winner and the founder of chemotherapy, postulated that 
“magic bullets” can be created and used to fight human disease, scientist have been inspired to 
develop precise and tailored drugs to target cancer 1. This vision came true with the development 
of a therapeutic that forms highly specific associations with targeted antigens by Kohler and 
Milstein in the form of monoclonal antibodies (mAb) 2. Huge advances have been made in the past 
decade with mAb therapy of cancer to treat many common malignancies with over 206 mAbs 
studied in clinical trials from 1980 to 2005 2,3. Despite these advances, cancer is still affecting and 
killing numerous lives every day.  
 
The monoclonal antibody therapy for cancer is deemed tailored because it specifically targets 
antigens expressed on cancer cells. Mucin 1 is a transmembrane mucin that is overexpressed in a 
number of metastatic epithelial cancers 4,5. Its expression correlates with an aggressive form of 
disease, poor response to therapy, and poor survival 4. The differences between the antigen in 
tumor and normal cells in terms of biochemical features, cell distribution, and function 5 provide 
an opportunity to use antibodies to specifically target and attack Muc1 positive tumor cells. Anti-
Muc1 antibodies alone, however, have not proven to be sufficiently cytotoxic to kill tumor cells.  
 
Depending on type and stage, current cancer treatments include surgery, radiation, chemotherapy, 
and immunotherapy. The goal of chemotherapy is to kill the fast-growing cancer cells. However, 
the drugs are often toxic so that they kill they normal cells in the body, leading to critical side 
effects. In this project, we aim to combine the high specificity properties of anti-Muc1 antibodies 
with the highly potent chemotherapeutic agent in order to identify a ‘magic bullet’ immune-based 
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treatment that produces improved efficacy and leads to the specific destruction of tumor-associated 
Muc1 cancer cells. 
 
 
INTRODUCTION 
Problem: Cancer 
According to the American Cancer Society, lung cancer is the second most common cancer in both 
men and women with about 13% of all new cancers being of the lung 6. Not only is the cancer 
prevalent, but it is one of the deadliest, accounting for 25% of cancer deaths 7. Furthermore, lung 
cancer is the leading cause of cancer death by far with more people dying of it than of colon, breast, 
and prostate combined 6. Currently, the amount of resources available to treat lung cancer nowhere 
near correlates with the impact of the disease. Given this, we are in desperate need to find better 
screening tests and treatment options.  
 
Non-small cell lung cancer (NSCLC), specifically, accounts for 84% of all lung cancer diagnoses, 
making it the most common type of lung cancer 8. Current treatment is based on the progression 
of the cancer. Treatments can include: surgery, radiation, chemotherapy, and immunotherapy. 
Outcomes do improve dramatically if the cancer is caught before metastasis because surgery is 
often a very effective form of treatment. However, most patients with NSCLC are often at an 
advanced stage by the time of diagnosis. Overall prognosis is very poor, with the five-year survival 
rate of only 23% 8. More work needs to be done in order to address prevention, early detection, 
and treatment of lung cancer.  
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As stated above, Mucin 1, a transmembrane member of the mucin family, is a protein 
overexpressed and altered in many epithelial cancers. Its expression is often associated with 
aggressive metastasis and poor prognosis 5. Muc1 expression correlates with cancer progression 
and is associated with the following cancers: lung, breast, ovarian, prostate, gastrointestinal, liver, 
and pancreas. Table 1 illustrates that Mucin 1 expression is associated with many different cancers. 
In this project, we will focus primarily on NSCLC, which exhibits 99% Muc1 expression (see 
Table 1).  
 
MUCIN 1 IS OVEREXPRESSED IN MANY CANCERS 
TUMOR TYPE MUC1 EXPRESSION # TISSUES EXAMINED SOURCE 
Nasopharyngeal 100% 38 Zhong XY, et al. 1993 
Non-small cell lung 99% 231 EMD Serono, Inc. Data on file 
Breast 91% 1447 Rakha EA, et al. 2005 
Renal cell carcinoma 84% 133 Langner C, et al. 2004 
Ovarian 83% 63 Chauhan SC, et al. 2006 
Squamous cell 
carcinoma of head and 
neck 
82% 29 Croce MV, et al. 2001 
Colorectal 81% 243 Baldus SE, et al. 2002 
Pancreatic 81% 53 Qu CF, et al. 2004 
Prostate 79% 89 DeNardo SJ, et al. 2005 
Gastric 77% 136 Ultsunomiya T. et al. 1998 
Mesothelioma 75% 20 Saad RS, et al. 2005 
Multiple myeloma 73% 26 Cloosen S, et al. 2006 
Esophageal 32% 53 Kijima H, et al. 2001 
 
Table 1: Mucin 1 is Overexpressed in Many Cancers. The overexpression of Mucin 1 protein 
is seen in a variety of different epithelial cancers (adapted from table made by Kerry Jordan at 
EMD Serono).  
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Muc1 Relationship 
Under normal conditions, mucins are large, heavily glycosylated proteins that are protectors and 
controllers of the cell surface. They are often found in particularly harsh environments and are 
expressed by epithelial cells of various organs, including the stomach, intestinal tract, liver, 
pancreas, gall bladder, kidney, eyes, esophagus, prostate, uterus, and lung 9,10. In healthy tissues, 
mucins aid in protecting the underlying epithelia at sites of respiration, digestion, and excretion 
5,11. These sites experience rapid changes in environment in regard to pH, ionic concentrations, 
oxygenation, and toxin exposure 5. With these variable conditions, mucins play a key role in 
maintaining homeostasis and promoting cell survival 9 (see Figure 1).  
 
 
Figure 1: Roles of Mucins. Mucins play a variety of roles in controlling the environment both in 
and around the cell, including: signal transduction, molecular sensing, protection, filtration, and 
maintenance. Reproduced from Swanson et al (2004) with permission.  
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Mucin 1, specifically, is a heavily O-glycosylated transmembrane protein that acts to protect that 
underlying epithelia. The long, negatively charged sugar branches create a physical barrier that 
imparts an anti-adhesive property 5. Mucin 1 consists of two domains: the long N-terminal subunit 
(Muc1-N) and the short C-terminal subunit (Muc1-C) 5 (see Figure 2). These subunits remain 
associated through hydrogen bonds extracellularly and create a heterodimer at the sea urchin sperm 
protein enterokinase and agrin (SEA) domain, which is a glycine-serine proteolytic cleavage site 
12. The Muc1-N subunit contains the variable number tandem repeat (VNTR) region, which 
encodes a variable number of sequences encoding 20 amino acids, rich with serines and threonines, 
that are extensively O-glycosylated under normal conditions 5 (see Figure 2).    
 
 
Figure 2: Mucin 1 Structure. Mucin 1 consists of Muc1-N and Muc1-C domains. The VNTR 
region is rich in serines and threonines that become extensively O-glycosylated under normal 
conditions. Reproduced from Kato et al (2017) with permission. 
 
 
 
 
There are many differences between normally expressed Muc1 and tumor-associated Muc1 in 
terms of biochemical features and cell distribution. In tumor cells, Muc1 becomes 
hypoglycosylated; this unmasks the peptide core, which destabilizes the cell surface and makes 
the protein vulnerable to proteolytic cleavage and clathrin-mediated endocytosis 5. Furthermore, 
the loss of polarity of cancer cells causes the overexpressed Muc1 to be redistributed over the 
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entire cell surface 5 (see Figure 3). Another difference between tumor associated Muc1 and that 
found on noncancerous cells is the changes in interaction between Muc1-C and Muc1-N. When 
Muc1 becomes hypoglycosylated, it allows Muc1-N to be cleaved and released from the cell 
surface 13. All of these alterations in Muc1 expression, features, distribution, and function have 
been shown to impact disease progression through various mechanisms as described below.  
 
Figure 3: Changes in Muc1 During Cancer Progression. Tumor associated Muc1 is 
hypoglycosylated and overexpressed over the whole cell surface. Reproduced from Nath et al 
(2014) with permission. 
 
Muc1 expression correlates with aggressive, metastatic cancers and there are numerous 
mechanisms with Muc1 involvement in metastatic progression. It has been hypothesized that the 
upregulation of Muc1 affects cancer cell invasion, proliferation, and survival by reducing cell-cell 
adhesion and cell-extracellular matrix adhesion 14. To give a couple of examples, first, Muc1-
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mediated cancer cell survival effects are believed to be through the interaction of Muc1-C with 
various signaling molecules, which lead to alterations in gene transcription that promote survival 
15. Second, Muc1 has been shown to promote growth of these cancer cells through its interaction 
with various growth factor receptors, leading to uncontrolled proliferation 16. Lastly, Muc1 
suppresses apoptosis of cancer cells through its numerous interactions with pathways involved in 
cell death, including p53, FOXA3a, and NF-kB 16. These examples only illustrate three 
mechanisms, but there are numerous roles Muc1 plays in the pathogenesis of cancer, both already 
investigated and have yet to be identified.  
 
 
 Anti-Muc1 Antibody 
Several anti-Muc1 antibodies have been developed over the past 40 years. The differences in O-
glycosylation patterns in the VNTR regions between tumor associated Muc1 and normal epithelial 
cell associated Muc1 lead to the presentation of different epitopes on Muc117. In cancer cells, the 
hypoglycosylation and truncated sugar chains of Muc1 expose the formerly masked peptide 
backbone to antibodies for attack 18,19 (see Figure 4). Because of the differences in Muc1 
properties, the anti-Muc1 antibody is able to discriminate and specifically attack Muc1 positive 
cancer cells. The antibodies on their own have not proven to be an effective form of cancer 
treatment for many reasons. In an international workshop on monoclonal antibodies against Muc1 
in 1996, results showed that antibodies recognizing the same peptide region had different binding 
patterns 20,21. Further studies have shown that the antibodies are not sufficiently discriminating 
between normal and tumor associated Muc1 21. We do recognize this problem and have addressed 
it by generating new antibody sequences at the complementarity-determining regions that have 
been shown in the literature to have enhanced specificity for tumor associated Muc1.  
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Figure 4: Antibody Binding to Muc1 Sequence. When Muc1 becomes hypoglycosylated and 
its sugar chains become truncated, the VNTR region becomes exposed for anti-Muc1 antibody 
binding, shown with HMFG2, HMFG1, and SM3. Reproduced from Franke et al (2001) with 
permission.  
 
 
 Antibody-Drug Conjugates (ADCs) 
In this project, we aim to develop a therapeutic molecule that combines the specificity approach 
of antibodies with the toxicity approach of chemotherapy in order to develop an antibody-drug 
conjugate. There are three components of an antibody-drug conjugate. First, an antibody that has 
specificity for an antigen substantially expressed on tumor cells, with limited expression on normal 
tissues. Second, a linker that is stable enough so that the drug is not prematurely released 
systemically, but not so much that the drug can still be cleaved off once intracellularly to induce 
its cytotoxic effects. Lastly, a drug that is often too toxic to be used on its own that has high potency 
at low concentrations and high cytotoxicity 22,23 . The goal in generating an antibody-drug 
conjugate is to take two therapies that have not proven to be efficacious and safe on their own, 
couple them together and create a new target therapy. ADCs account for the advantages and 
disadvantages of each treatment on their own by combining the precision capabilities of 
monoclonal antibodies in targeting the cell surface of cancer cells and the nonspecific toxicity 
characteristics of chemotherapy drugs 24 (see Figure 5).  
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Figure 5: Antibody-Drug Conjugate Components. ADCs link the targeting aspect of 
monoclonal antibodies with the cytotoxic capabilities of chemotherapy drugs. Reproduced from 
Million et al (2013) with permission. 
 
 
Figure 6 illustrates the mechanism of action of antibody-drug conjugates. First, the ADC is 
delivered systemically and circulates through the bloodstream. Again, the linker must be stable in 
this environment so that the cytotoxic drug is not prematurely released. Next, the antibody reaches 
its target site and binds to the antigen on the surface of the cancer cell. This causes the ADC to 
become internalized via a clathrin-coated pit mechanism into the endosome-lysosome pathway. 
Once internalized, the new internal conditions destabilize the linker, resulting in cytotoxic drug 
release into the cytoplasm. Lastly, the free drug in its active form is able to bind to its target site 
in order to induce apoptosis of the tumor cell 25,26.   
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Figure 6: ADC Mechanism of Action. The mechanism of the ADC proceeds as follows: antibody 
binding target antigen on cancer cell, internalization through the endosome-lysosome pathway, 
cytotoxic drug release, and then cell death. Reproduced from Scotti et al (2015) with permission. 
 
 
Solution: Anti-Muc1-DM1 
In this project, we aim to develop an antibody-drug conjugate that targets Muc1 on cancer cells by 
coupling an anti-Muc1 antibody with mertansine (DM1). Mertansine is a maytansinoid that kills 
cells via blocking cell division by interacting with tubulin to disrupt microtubule formation and 
depolymerize already formed microtubules 27,28. On its own, mertansine has not been proven to be 
effective as a cancer treatment because of its high systemic toxicity side effects, resulting in a low 
therapeutic index 28,29.  DM1 has been an extensively used candidate for ADCs, including in a 
current HER2-targeting ADC (Herceptin), given its cytotoxicity, potency, solubility profile, and 
 15 
internalization qualities 28 . We hope to expand mertansine’s therapeutic window by using it as the 
cytotoxic payload of our antibody-drug conjugate.  
 
Recent studies have shown that noncleavable linkers are a better choice over cleavable linkers 
because of their stability at physiological pH and their stability in the circulation 28,30 . The 
noncleavable linker does not have an obvious drug release mechanism; some of the noncleavable 
linkers rely on differences in glutathione concentrations intracellularly and extracellularly in order 
reduce disulfide bonds for drug release 31. SMCC (succinimidyl-4-(N-maleimidomethyl)- 
cyclohexane-1-carboxylate) is the noncleavable linker used as the crosslinking agent in this 
project. The linker has often been used in conjugations with DM1 due to its increased stability and 
half-life in plasma. Linking the drug to the antibody involves conjugation to the exposed amino 
groups on the lysine residues of the anti-Muc1 antibody (see Figure 6).  
 
 
Figure 7: ADC Conjugation with SMCC and DM1. Anti-Muc1 antibody is conjugated to the 
microtubule inhibitor, DM1, with the SMCC linker, a noncleavable disulfide bond linker. 
Reproduced from Lee (2017) with permission. 
 
 
 16 
HYPOTHESIS AND SPECIFIC AIMS 
 Hypothesis 
Our aim is to build upon advancements made in the last thirty years with several anti-Muc1 
antibodies being developed that display high affinity, specificity, and stability in vitro. However, 
these antibodies have not proved to be successful as cancer therapeutics because they have not 
shown significant decreases in tumor growth or survival in vivo. We hypothesize that an antibody-
drug conjugate developed to target tumor-associated Muc1 and deliver a cytotoxic drug will 
destroy target cancer cells. By using an ADC, we intend to enhance the anti-cancer effects of the 
antibody by conjugating a cytotoxic drug to it. Further, we intend to reduce the toxicity of the 
chemotherapy drug by antibody-mediated targeted delivery. Our hypothesis for this project is that 
the combination of the anti-Muc1 antibody and cytotoxic agent produces an improved efficacy 
over antibody alone and reduced toxic side effects of drug alone, ultimately leading to the 
destruction of tumor-associated Muc1 cancer cells.  
 
 Specific Aims 
I. Design and synthesize an anti-Muc1 antibody-drug conjugate 
a. Design constructs for an antibody that specifically targets Muc1 on both its N-
terminal region and its C-terminal region 
b. Synthesize an anti-Muc1 ADC using a SMCC-DM1 conjugation approach and 
optimize its reaction  
II. Investigate the in vitro anti-cancer effects of the anti-Muc1 antibody-drug conjugate 
compared to its parent antibody 
 17 
a. Use flow cytometry to study the binding of the anti-Muc1 antibody construct to 
cancer cells versus noncancer cells 
b. Measure metabolic activity of cancer cells treated with the anti-Muc1 ADC and its 
parent antibody to determine the drug’s cytotoxicity profile  
c. Further characterize the anti-Muc1 ADC to determine the drug-to-antibody ratio 
using mass spectrometry 
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MATERIALS AND METHODS 
Antibody Synthesis  
Three anti-Muc1 antibodies (HMFG2, 12E, and SM3) were generated using the backbone of 
Trastuzumab (Herceptin). The plasmid DNA-encoding pVITRO1-Trastuzumab-IgG1/k was 
obtained from Addgene (plasmid #61883 deposited by Andrew Beavil). Changes were made in 
the VH and VL regions of Trastuzumab in order to generate the new anti-Muc1 antibodies. HMFG2 
was generated using VH accession number CAN99757.1 and VL accession number AAB97462.1 
32. 12E was generated using VH accession number ACH99176.1 and VL accession number 
AAG28706.2 33. SM3 was generated using VH accession number AAB97461.1 and VL accession 
number AAB97462.1 32. 
 
DNA Isolation 
The anti-Muc1 antibody gene is transformed into Invitrogen One Shot TOP10 chemically 
competent cells (Invitrogen, Carlsbad, CA). 50 uL of the cells is combined with 1-5 uL of DNA 
and the mixture is allowed to incubate on ice for 30 minutes. The cell/DNA mixture is heat-
shocked at 42°C for 30 seconds and then placed on ice. 250 uL of SOC media is added to each 
tube and grown for one hour while shaking at 225 rpm at 37°C. The cells are then plated on an LB 
agar plate containing hygromycin B gold (InvivoGen, San Diego, CA) at a concentration of 100 
ug/mL and incubated overnight at 37°C.  
 
The following day, one colony is selected from the LB agar plate and grown in 5 mL of LB media 
containing 100 ug/mL of hygromycin B gold for three hours while shaking at 225 rpm at 37°C. 
The mixture is then transferred to a 1.2 L of LB media containing 100 ug/mL of hygromycin B 
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gold in a 2 L flask and allowed to grow overnight. The bacterial cells are harvested through 
centrifugation at 4700 x g for 10 minutes at 4°C. The DNA is isolated using a NucleoBond Xtra 
EF plasmid purification kit (Machery-Nagel, Bethlehem, PA). DNA concentration is measured 
using the Synergy 4 Multi-Detection Microplate Reader (BioTek, Winooski, VT). 
 
Transfection 
Expi293 cells (ThermoFisher, Waltham, MA) are subcultured to a concentration of about 5 x 106 
cells/mL in a 1L flask. The Expi293 cells are spun down at 200 rpm for 6 minutes and the media 
is aspirated. The cells are diluted to a concentration of 600 x 106 cells in 200 mL fresh media in a 
1L flask. 200 uL of DNA at a concentration of 1 mg/mL is combined with 12 mL Opti-MEM 
(ThermoFisher, Waltham, MA) and incubated for 5 minutes. 640 uL of ExpiFectamine 293 
Reagent (ThermoFisher, Waltham, MA) is combined with 11.2 mL Opti-MEM and incubated for 
5 minutes. The ExpiFectamine 293 Reagent is a cationic lipid transfection reagent that binds the 
negatively charged DNA backbone. The complex enters the cell through endocytosis and then 
diffuses through the cytoplasm to enter the nucleus for gene expression. The two mixtures are 
combined and incubated for 20 minutes to form the transfection complex. The ExpiFectamine 
293/plasmid DNA complex is slowly added to the 1L flask of Expi293 cells. The cells are shaken 
at 125 rpm and incubated in a 37°C and humidified (8% CO2) incubator. At 18-22 hours post 
transfection, 1.2 mL of Expifectamine 293 Enhancer 1 (ThermoFisher, Waltham, MA) and 12 mL 
of Expifectamine 293 Enhancer 2 (ThermoFisher, Waltham, MA) is added to the flask and then 
returned to the incubator. We conducted a transfection optimization protocol and found that the 
cells are to be taken out on day 7 in order to produce the highest protein yield. On day 7, the cells 
are centrifuged at 4700 x g for 30 minutes and the supernatant is filtered through a 0.2 um filter. 
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Purification 
The proteins are purified using fast protein liquid chromatography (FPLC). Affinity 
chromatography using protein A, a cell wall protein that has high specificity for the Fc region of 
the immunoglobulin, is used for purification. Protein concentration is quantified using Pierce BCA 
Protein Assay Kit (ThermoFisher, Waltham, MA) and measured using the BioTek Synergy 4 
Multi-Detection Microplate Reader.  
 
Antibody-Drug Conjugate Synthesis 
Anti-Muc1 antibody is combined with DM1-SMCC (Cayman Chemical Company, Ann Arbor, 
MI) at a drug:Ab molar ratio of 10:1, 20:1, and 40:1 (referred later on as R10, R20, and R40). First, 
the antibody is diluted with PBS at a ratio of 3 mL PBS: 1mL antibody. While the mixture is 
stirring, DMSO (Sigma-Aldrich, St. Louis, MO) is added so that the percent DMSO is equal across 
all three forms of ADC. The DM1-SMCC stock solution is added quickly at a volume 
corresponding to its molar ratio. The mixture is stirred for 2-4 hours at room temperature away 
from light.  
 
After the conjugation reaction, the ADC is dialyzed against PBS using a 20,000 molecular weight 
cut-off dialyzer cassette (ThermoFisher, Waltham, MA). The mixture is left to dialyze for 24-48 
hours at room temperature away from light. The product is sterilized by filtration using a 0.2 um 
filter. The final ADC is then purified using FPLC with the same procedure as described above. 
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 Cell Culture 
The following cells (normal, lung cancer, and breast cancer) were purchased from American Type 
Culture Collection (ATCC, Manassas, VA): CCD-19Lu, Calu 3, H1299, H1975, A549, HCC827, 
MCF7, MDA-MB 231, and SkBr3. Upon thawing the cells, the suspension is centrifuged at 200 
rpm for 6 minutes in order to remove the DMSO. The cells are then placed in their respective 
media that contains 1% of 100 U penicillin / 0.1 mg/mL streptomycin solution (ThermoFisher, 
Waltham, MA) and 10% of fetal bovine serum (FBS) (ThermoFisher, Waltham, MA). The cells 
are plated on a 175 cm2 flask with 25mL of its complete media. Cells are incubated at 37°C and 
placed in a humidified (5% CO2) incubator. The cells are allowed to grow until they reach about 
80% confluency. At this time, the cells are subcultured. 
 
Antibody Binding Assay 
To determine how well the Anti-Muc1 antibody binds to cancer cells, a fluorescence imaging assay 
is conducted using fluorescein isothiocyanate (FITC) (ThermoFisher, Waltham, MA). FITC is a 
fluorescein molecule with a molar mass of 473.4 g/mol that is reactive with the amines present on 
the surface of the Anti-Muc1 antibody. 1.5-3.0 mg of the Anti-Muc1 antibody is added to a vial 
with a stir bar. While the mixture is spinning, the fluorescein dye (15-30 uL) is added at a ratio of 
30 moles dye to 1 mole of antibody. The mixture incubates for 2 hours while stirring and away 
from light. After binding is allowed to occur, the mixture is dialyzed against PBS using a 20,000 
molecular weight cut-off dialyzer cassette. The mixture is left to dialyze overnight at room 
temperature away from light.  
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Flow cytometry cell sorting (FACS) is used to detect the FITC signal, which has excitation and 
emission spectrum peak wavelengths at 495nm and 519nm. Samples are prepared for analysis just 
prior to FACS measurement. Samples are made by combining 1 x 105 cells (CCD19Lu, Calu 3, 
H1299, H1975, A549, HCC827, MCF7, MDA MB 231, and SkBR3) and 10 ug of DNA. The 
samples incubate for one hour at room temperature and the binding characteristics are quantified 
using the LSR II flow cytometer (BD Biosciences, San Jose, CA).  
 
Cytotoxicity Assay  
On the first day of the preparation for the cytotoxicity experiment, the cells (CCD19Lu, Calu 3, 
H1299, H1975, A549, HCC827, MCF7, MDA MB 231, and SkBR3) are plated in a 96 well plate. 
Each well contains 5 x 103 cells in 150 uL of their respective media. The cells are allowed to 
incubate overnight at 37°C. The next day, the Anti-Muc1 antibody-drug conjugate is introduced. 
The ADC is added to each cell line at a final concentration ranging from 0.0005 ug/mL to 50 
ug/mL.  
 
At 24 hours post ADC treatment, cell death is quantified using the MTT assay kit (Abcam, 
Cambridge, UK). MTT (3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide) is a dye 
that turns purple when NADPH-dependent cellular oxidoreductase enzymes reduce it. Therefore, 
those wells that have more living cells, thus more metabolic activity, will exhibit a darker purple 
coloring. First, all media is aspirated from the wells carefully and without scratching the bottom 
surface. The MTT solution is prepared with complete media so that the MTT is at a concentration 
of 0.5 mg/mL. 150 uL of the MTT solution is added to each well and the plates are allowed to 
incubate for 3-4 hours at 37°C. Following incubation, each well is aspirated. 150 uL of DMSO is 
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added to each well and mixed well. The absorbance is recorded at an OD of 590nm using the 
BioTek Synergy 4 Multi-Detection Microplate Reader. IC50 and statistical analysis is conducted 
using GraphPad Prism 8 software (GraphPad, San Diego, CA).  
 
Mass Spectrometry Analysis 
A sample of Anti-Muc1 antibody DNA at 1 mg/mL was sent to Analytical and Biological Mass 
Spectrometry at the University of Arizona and analyzed using electrospray ionization mass 
spectrometry (ESI/MS). 
 
 
RESULTS 
 Transfection Optimization and Gel Verification 
At the beginning of antibody development, we produced the three Anti-Muc1 antibodies (HMFG2, 
SM3, and 12E) using both ExpiCHO (Chinese hamster ovary cells) and Expi293 (human 
embryonic kidney cells) cells. In order to optimize our transfection protocol, we compared the 
protein yield from using each cell line expression system. Following purification using FPLC, the 
protein yield was determined. Table 2 shows that the Expi293 expression system was found to be 
superior to ExpiCHO in terms of protein yields, so we decided to use that system for the rest of 
the project.  
 
The native and SDS gels in Figures 7 and 8, respectively, also compare the two expression systems 
in terms of protein purity. The ExpiCHO cell lines produced proteins that were not as pure with 
more breakdown products. Further verifying our transfection and purification procedures, we see 
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the antibodies coming out at their respective molar masses (approximately 148,000 Da) in the 
native gel and the heavy and light chains coming out in the denatured gel. These gels provided 
more evidence to proceed with using the Expi293 expression system for the rest of the project. 
 
Antibody ExpiCHO Yield (mg/L) Expi293 Yield (mg/L) 
12E 7.22 6.00 
HMFG2 7.72 10.3 
SM3 0.93 3.35 
 
Table 2: Anti-Muc1 Yield Using Two Expression Systems. Three anti-Muc1 antibodies were 
produced using two different expression systems for transfection, ExpiCHO and Expi293, and 
their yields were compared. 
 
Figure 8: Native anti-Muc1 Gel. Anti-Muc1 is coming out at its 148kDa molar mass with 
increased purity using the Expi293 expression system. 
 
Figure 9: SDS anti-Muc1 Gel. With the disulfide bonds reduced between the heavy and light 
chains, the respective bands are visualized. 
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Antibody Binding Assay 
To test how well the anti-Muc1 antibody binds to the cancer cells compared to normal cells, we 
used a FITC conjugation approach and measured the fluorescence using flow cytometry. A greater 
shift to the right in the FITC histogram illustrates a greater percentage of anti-Muc1 expression on 
the cell. In comparing our three synthesized anti-Muc1 antibodies, we noticed that there was a 
greater percentage of HMFG2 expressed on the cancer cells, compared to 12E and SM3. For 
example, in looking at MCF7 cells (breast adenocarcinoma), we saw that 75.1% of HMFG2 
binding to Muc1 expressed on the cell membrane, whereas for the SM3 and 12E antibodies, there 
was only 3.47% and 32.9% of binding to Muc1. This trend was seen throughout most of the other 
cancer cell lines. Given these binding characteristics, we concluded that the HMFG2 antibody 
would be the most efficacious compared to 12E and SM3, so we decided to further investigate 
only the HMFG2 antibody for DM1-SMCC conjugation experiments.  
 
The normal lung cells, CCD-19Lu, exhibited the least amount of anti-Muc1 expression throughout 
its surface, which is crucial to the theories behind antibody-drug conjugates. We hoped to develop 
a drug that specifically targets and kills cancer cells, while showing little toxicity for normal, non-
cancerous cells.  
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Figure 10: FITC/FACS Antibody Binding Assay. A mixture of FITC bound to anti-Muc1 antibody was allowed to incubate with 
cancerous and noncancerous cells for one hour. Fluorescence was measured and compared to that measured from the isotype control. 
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Table 3: Muc1 Expression Summary. Percentage of Muc1 expression on each cell type was reported from FITC/FACS analysis. An 
ideal anti-Muc1 antibody binds to cancerous cell lines expressing Muc1, but not to the noncancerous CCD019Lu cells
Cell Line Origin Type 
Commercialized MUC1 Synthesized MUC1 
IgG Control 
(HER2) BD 
Pharmingen™ 
NOVUS 
Biologicals™ 
Santa Cruz 
Biotechnology
™ 
HMFG2 SM3 12E 
CCD-19Lu Lung Normal 16.4 0.55 0.18 2.17 1.13 0.70 0.16 
Calu 3 Lung Adenocarcinoma 20.2 6.40 1.77 15.6 5.33 2.69 99.6 
H1299 Lung NSCLC 71.5 23.5 2.36 39.5 13.3 4.39 12.7 
H1975 Lung NSCLC 68.2 27.5 1.24 46.2 23.5 5.60 53.0 
A549 Lung Adenocarcinoma 1.51 1.47 0.53 8.43 4.84 2.58 5.35 
HCC827 Lung Adenocarcinoma 27.3 7.47 0.75 12.5 5.39 2.87 3.68 
MCF7 Breast Adenocarcinoma 83.8 75.5 37.5 75.1 3.47 32.9 18.2 
MDA-MB-
231 Breast Adenocarcinoma 83.2 7.18 0.30 7.99 1.74 0.83 0.42 
SkBR3 Breast Adenocarcinoma 45.2 10.1 1.58 15.5 5.93 1.71 99.8 
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Anti-Muc1-DM1 Cytotoxicity 
The cytotoxicity of anti-Muc1 antibody conjugated to the SMCC linker and mertansine 
chemotherapy drug was investigated using an MTT colorimetric assay that assesses cell activity 
through the presence of NAD(P)H-dependent cellular oxidoreductase enzymes. The more of these 
enzymes present, the more MTT is reduced to its insoluble form, which is purple in color. The 
greater the absorbance at 590 nm, the greater number of viable cells, so the less cytotoxic the ADC.  
 
The cytotoxicity assay was run for a total of three trials. Among all of the trials, we noticed that 
the ADC did not induce significant cytotoxicity on cancer cells until 48-72 hours of incubation. In 
all three trials, we saw that the R20 ADC had a considerable decrease in IC50 compared to the 
antibody alone. Furthermore, we saw that the R40 ADC had a decrease in IC50 compared to the 
R20 ADC.  
 
Looking at the CCD-19Lu, normal lung cells, we saw that the ADC does not exhibit significant 
cytotoxic effects until it reaches a large concentration. In all conditions, the IC50 was considerably 
larger for the treatments against the CCD-19Lu cells compared to the cancer cells. For these cells, 
we also saw that DM1 has an effect at lower concentrations. It is important to remember that the 
mechanism of DM1, or mertansine, arrests the cell cycle during division via microtubule 
inhibition. The drug is killing off the normal, noncancerous cells because they also contain 
microtubules. Further, the drug has a greater effect on cells that have faster proliferative rates, 
meaning it is less efficacious in normal cells. This is why we hoped to develop an ADC that 
combines this toxicity effect with the specificity effect of the anti-MUC1 antibody. The cancer 
cells that the ADC seemed to have the greatest cytotoxic effect were: H1975, HCC827, and MCF7.
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Figure 11: HMFG2 ADC Cytotoxicity Assay on CCD-19Lu Cells. Cytotoxicity effect of 
ADC on normal lung cells.  
 
 
Figure 12: HMFG2 ADC Cytotoxicity Assay on H1975 Cells. Cytotoxicity effect of ADC on 
non-small cell lung cancer cells.  
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Figure 13: HMFG2 ADC Cytotoxicity Assay on HCC827 Cells. Cytotoxicity effect of ADC 
on lung adenocarcinoma cells.  
 
Figure 14: HMFG2 ADC Cytotoxicity Assay on A549 Cells. Cytotoxicity effect of ADC on 
lung adenocarcinoma cells.  
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Figure 15: HMFG2 ADC Cytotoxicity Assay on MCF7 Cells. Cytotoxicity effect of ADC on 
breast adenocarcinoma cells.  
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In vitro HMFG2-DM1 (MUC1-DM1) IC50 (ug/mL) 
Cell Line Time  (hr) DM1 HMFG2 
HMFG2-DM1 
R20 
HMFG2-DM1 
R40 
CCD-19Lu 
(Normal) 
24 - >10 >10 >10 
48 - >10 >10 >10 
72 - >10 >10 >10 
H1975 
(Lung) 
24 - >10 6.93 – 8.13 2.13 – 4.06 
48 - >10 3.95 – 4.21 2.10 – 3.42 
72 - >10 2.79 – 3.74 1.17 – 3.14  
HCC827 
(Lung) 
24 - >10 6.93 – >10 1.63 – >10 
48 - >10 5.37 – 5.69 0.85 – 3.09 
72 - >10 3.15 – 5.02 0.24 – 2.80 
A549 
(Lung) 
24 - >10 >10 >10 
48 - >10 >10 >10 
72 - >10 3.29 – 9.39 1.96 – 9.01 
MCF-7 
(Breast)  
24 - >10 5.99 – >10 3.42 – >10 
48 - >10 3.89 – 4.39 3.26 – 3.60 
72 - >10 3.04 – 4.17 0.50 – 3.18 
 
Table 4: In vitro HMFG2-DM1 IC50. Statistical analysis from the MTT cytotoxicity assays 
presented in Figures 10-14 was conducted using Graphpad Prism 6. The IC50 values are given in 
ranges because the assay was repeated three times. 
 
 
 
Mass Spectrometry 
Using electrospray ionization mass spectrometry, the number of mertansine molecules 
conjugated on HMFG2, the drug-to-antibody ratio (DAR), was quantified. For the unconjugated 
HMFG2 antibody, the DAR is 0. For the ADCs, the DARs for HMFG2-DM1 R10, HMFG2-
DM1 R20, and HMFG2-DM1 R40 are 1.25, 1.79, and 2.34, respectively.  
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Figure 16: Mass Spectrometry of HMFG2.  
 
 
Figure 17: Mass Spectrometry of HMFG2-DM1 R10. 
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Figure 18: Mass Spectrometry of HMFG2-DM1 R20. 
 
 
Figure 19: Mass Spectrometry of HMFG2-DM1 R40. 
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DISCUSSION 
Antibody Binding Assay 
In conducting the antibody binding assay, our goals were to investigate the binding properties of 
the synthesized antibodies to both cancerous cells and noncancerous cells and compare those 
results to three commercialized anti-Muc1 antibodies that are currently on the market. To be an 
ideal candidate for the antibody-drug conjugate, we wanted our anti-Muc1 antibody to be specific 
to cancer cells. This was seen with increased binding percentage towards Muc1 on the cancerous 
cells and a decreased binding percentage towards Muc1 on the noncancerous CCD19-Lu cells. 
With the BD Pharmingen™ commercialized antibody, we see in Table 3 that the antibody was 
binding to the Muc1 on the H1299, H1975, MCF7, and MDA-MB-231 cancerous cell lines at a 
significant proportion. However, this antibody is not specific to cancer cells because 16.4% of 
CCD19-Lu normal cells are expressing Muc1 that is recognized by the BD Pharmingen™ 
antibody. The BD Pharmingen™ antibody would not be a good candidate for the antibody-drug 
conjugate because it would not be specifically targeting the tumor associated Muc1, leading to 
potential toxicity side effects. It is likely that we are seeing this result because the BD 
Pharmingen™ antibody targets Muc1 on cells, regardless if it is glycosylated or not. In looking at 
the other two commercialized antibodies, while they are not binding to noncancerous cells, we see 
that there is only one or two cancerous cell lines that they are interacting significantly with.  
 
In looking at the three antibodies that we have been synthesizing in the lab, we would expect that 
the antibodies show more specificity towards the cancer cells. This is because the antibodies were 
designed to specifically target the VNTR region, which is hypoglycosylated in tumor cells. 
HMFG2 is the one that stands out with its binding profile towards cancerous cells (H1975 and 
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MCF7), while only 2.17% of Muc1 expression on CCD19-Lu cells. The other two antibodies, SM3 
and 12E, did not show as great of Muc1 expression on the cancerous cells. From this experiment, 
we decided that HMFG2 would be the best candidate as an antibody in an ADC to target tumor 
associated Muc1. 
 
Anti-Muc1-DM1 Cytotoxicity 
In the cytotoxicity assays, we were not able to obtain IC50 values for the mertansine (DM1) free 
drug. DM1 is a potent drug that disrupts the microtubule formation and depolymerizes already 
formed microtubules. Thus, this drug is most effective towards proliferative cells; these cells could 
be cancer cells or noncancerous cells. This quality is shown in Figures 10-14, which highlight that 
at the 24-hour time point, most of the cells are dead. Because of this, we were not able to obtain 
useful IC50 values.  
 
One significant finding from the cytotoxicity assays was that the ADCs have a greater cytotoxic 
effect on Muc1 positive tumor cells than HMFG2 alone. From Table 4, we see that the HMFG2 
antibody has an IC50 value of greater than 10 ug/mL for each cancer cell line. With the ADCs, 
HMFG2-DM1 R20 and R40, we see that there is a significant decrease in IC50 values. This shows 
that the ADC is more effective at killing Muc1 positive tumor cells than its parent antibody alone. 
 
Another trend we see from Table 4 is that the ADC had little cytotoxic effect on the noncancerous 
CCD19-Lu cells. At all three timepoints, the ADC has an IC50 value of greater than 10 ug/mL. 
These findings are crucial because they show that our synthesized ADC is specifically targeting 
the hypoglycosylated Muc1 on the cancer cells, allowing for targeted cell killing.  
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From the cytotoxicity assay, we also noticed that with longer incubation times, the ADC exhibits 
more of a cytotoxic effect on the cancer cells. In Table 4, at the 72-hour time points, we are seeing 
anywhere from a 2 to 20 fold decrease in IC50 value compared to its respective 24-hour time point. 
We can hypothesize that with longer incubation times, the ADC is more effective because it has 
more time to become internalized within the cell, allowing for more time for drug release.  
 
In comparing the A549 (lung adenocarcinoma) cell line to the other cancer cell lines, we see that 
the ADC is not exhibiting as large of a cytotoxic effect on these cells. It is likely we are seeing this 
effect because of the findings we found from the antibody binding assay, shown in Table 3. From 
this experiment, we showed that the A549 cells expressed that lower percentage of 
underglycosylated Muc1 detected by HMFG2 at 8.43%. With this finding, it is not surprising that 
the antibody did not show as great of a cytotoxic effect. 
 
Mass Spectrometry 
As to be expected, the drug-to-antibody ratios (DAR) that we obtained are larger for the ADCs 
that were synthesized at a larger molar ratio of drug to antibody. The DAR is an important 
characteristic of our ADC, especially when we are thinking about injecting this into a patient. With 
too many conjugated mertansine drugs to the HMFG2 antibody, we would likely see a decrease in 
solubility because of hydrophobicity. Further, this would cause the drug to become cleared from 
the system, resulting in it not reaching its target, thus decreasing its overall efficacy. As we move 
forward with potential in-vivo and clinical studies, we will have to maintain this balance. 
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FUTURE DIRECTIONS 
In healthy tissues, Muc1 is a heterodimeric complex with the interaction between the Muc1-C and 
Muc1-N subunits 5. It has been shown in recent studies that in cancer patients, there are elevated 
levels of Muc1-N in the serum due to its shedding from the Muc1-C subunit on the cell surface 
34,35 (see Figure 19). In this state, Muc1-C functions as an oncoprotein through its interactions with 
many effectors shown to be linked to cancer progression, including the P13K-AKT and MEK-
ERK pathways 36. From its participation in these signaling pathways, Muc1-C has been linked to 
the induction of the epithelial-mesenchymal transition and epigenetic programming, contributing 
to cancer progression 36. With our current ADC that targets the Muc1-N subunit, in thinking about 
clinical studies, its systematic delivery has to overcome the circulating Muc1-N in the serum in 
order for it to reach its target. We have recognized this as a potential complication and are currently 
in the process of generating an antibody that targets the Muc1-C subunit specifically. 
 
 
Figure 20: Interactions between Muc1-C and Muc1-N. In healthy tissue, Muc1 has been 
shown to be a heterodimer with the N and C subunits (left). In cancer-associated Muc1, it has 
been shown that the Muc1-N subunit is shed from the cell surface. Kufe (2009). 
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CONCLUSION 
We have developed an antibody-drug conjugate that targets the hypoglycosylated Mucin1 seen in 
cancers like lung and breast (Specific Aim 1). We have also satisfied Specific Aim 2 by 
investigating the in vitro effects of the ADC compared to its parent antibody. The cytotoxicity 
assays have shown three significant properties of the synthesized ADC. First, the ADC has a 
greater cytotoxic effect on Muc1 expressing cancer cells compared to HMFG2 alone. Second, the 
ADC is specifically targeting the Muc1 associated with cancer cells, shown with its little effect on 
CCD19-Lu cells. Lastly, the ADC has a significant cytotoxic effect on Muc1 expressing cancer 
cells with longer incubation times. From our results, we have accepted our hypothesis of the 
combination of the anti-Muc1 antibody and cytotoxic agent produces an improved efficacy over 
antibody alone and reduced toxic side effects of drug alone, ultimately leading to the destruction 
of tumor-associated Muc1 cancer cells. In the future, we hope to compare these results to an ADC 
that targets the C-terminal region on Muc1. Our efforts lay groundwork for a novel treatment of 
cancers that overexpress Muc1.  
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